Article Versions Notes

Saruwatari K, Sato R, Nakane S, Sakata S, Takamatsu K, Jodai T, Mito R, Horio Y, Saeki S, Tomita Y, et al. The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. Cancers. 2019; 11(2):140. https://doi.org/10.3390/cancers11020140

Saruwatari, Koichi, Ryo Sato, Shunya Nakane, Shinya Sakata, Koutaro Takamatsu, Takayuki Jodai, Remi Mito, Yuko Horio, Sho Saeki, Yusuke Tomita, and et al. 2019. "The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients" Cancers 11, no. 2: 140. https://doi.org/10.3390/cancers11020140

Saruwatari, K., Sato, R., Nakane, S., Sakata, S., Takamatsu, K., Jodai, T., Mito, R., Horio, Y., Saeki, S., Tomita, Y., & Sakagami, T. (2019). The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients. Cancers, 11(2), 140. https://doi.org/10.3390/cancers11020140